Eli Lilly and Company [NYSE: LLY] stock went on an upward path that rose over 0.35% on Thursday, amounting to a one-week price increase of more than 0.89%. The company report on October 6, 2022 that Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
The Fast Track designation accelerates tirzepatide’s path to U.S. FDA submission for the treatment of adults with obesity, or overweight with weight-related comorbidities.
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need. Fast Track designation is intended to bring promising medicines to patients sooner.
Over the last 12 months, LLY stock rose by 46.13%. The one-year Eli Lilly and Company stock forecast points to a potential upside of 3.97. The average equity rating for LLY stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $322.88 billion, with 950.17 million shares outstanding and 947.67 million shares in the current float. Compared to the average trading volume of 2.74M shares, LLY stock reached a trading volume of 4272611 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Eli Lilly and Company [LLY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LLY shares is $346.71 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LLY stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Eli Lilly and Company shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 22, 2022. While these analysts kept the previous recommendation, SVB Leerink raised their target price to Outperform. The new note on the price target was released on May 23, 2022, representing the official price target for Eli Lilly and Company stock. Previously, the target price had yet another raise from $265 to $364, while Morgan Stanley kept a Overweight rating on LLY stock.
The Average True Range (ATR) for Eli Lilly and Company is set at 9.54, with the Price to Sales ratio for LLY stock in the period of the last 12 months amounting to 11.11. The Price to Book ratio for the last quarter was 35.08, with the Price to Cash per share for the same quarter was set at 2.82. Price to Free Cash Flow for LLY in the course of the last twelve months was 132.86 with Quick ratio for the last quarter at 0.80.
LLY Stock Performance Analysis:
Eli Lilly and Company [LLY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.89. With this latest performance, LLY shares gained by 6.85% in over the last four-week period, additionally plugging by 8.86% over the last 6 months – not to mention a rise of 46.13% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LLY stock in for the last two-week period is set at 61.46, with the RSI for the last a single of trading hit 65.33, and the three-weeks RSI is set at 58.76 for Eli Lilly and Company [LLY]. The present Moving Average for the last 50 days of trading for this stock 314.00, while it was recorded at 327.90 for the last single week of trading, and 291.76 for the last 200 days.
Insight into Eli Lilly and Company Fundamentals:
Eli Lilly and Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 1.10.
LLY Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LLY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Eli Lilly and Company go to 16.67%.
Eli Lilly and Company [LLY] Insider Position Details
There are presently around $263,276 million, or 84.40% of LLY stock, in the hands of institutional investors. The top three institutional holders of LLY stocks are: LILLY ENDOWMENT INC with ownership of 103,773,810, which is approximately -0.372% of the company’s market cap and around 11.00% of the total institutional ownership; VANGUARD GROUP INC, holding 71,591,327 shares of the stock with an approximate value of $23.84 billion in LLY stocks shares; and BLACKROCK INC., currently with $21.23 billion in LLY stock with ownership of nearly -0.382% of the company’s market capitalization.
Positions in Eli Lilly and Company stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 1,077 institutional holders increased their position in Eli Lilly and Company [NYSE:LLY] by around 34,247,331 shares. Additionally, 986 investors decreased positions by around 29,827,833 shares, while 444 investors held positions by with 726,662,163 shares. The mentioned changes placed institutional holdings at 790,737,327 shares, according to the latest SEC report filing. LLY stock had 203 new institutional investments in for a total of 8,816,184 shares, while 78 institutional investors sold positions of 1,055,036 shares during the same period.